Theravance Biopharma, Inc. (TBPH) Stock Analysis
Theravance Biopharma, Inc.
▾ What's in the 28/100 risk score? (higher = riskier)
Contributions (weight × component score) sum to the total. This near-term score now includes fundamental health (leverage, FCF trend, DCF applicability). See the Financial Health section for the full balance-sheet read.
How to read TBPH
A profitable, cash-generating business — our discounted-cash-flow estimate is the primary lens, cross-checked against what growth the price implies and against peers.
-
1
The verdict + intrinsic value (our DCF) ↓
Our estimate of what a share is worth, versus today's price.
-
2
Reverse-DCF + the interactive calculator ↓
See the growth the price assumes, then flex every assumption yourself to pressure-test it.
-
3
Football field + peers ↓
A cross-check across methods and against comparable companies.
What growth must the market believe? Reverse DCF — Instead of asking "what is this stock worth?", asks "what growth rate is the current market price already assuming?"
Why it matters: It crystallizes the bull thesis as a single number you can argue with. If the market expects 40% growth for 10 years and you do not believe that, the stock is overvalued.
Reference: 10–15% = sustainable for strong companies · 20–25% = exceptional · 30%+ = historically very rare
Traditional DCF asks "what is this stock worth?" Reverse DCF flips it: it treats today's price as correct and solves for the growth rate that justifies it. In plain terms — if our model is right about everything else, the company's cash flow would have to grow (or shrink) by this much every year for the next 10 years for today's price to make sense. If that required growth looks unrealistic, the price is stretched; if it looks easy to beat, the price may be cheap.
Why it matters: A company can show big profits on paper while burning through cash. FCF is what actually fills the bank account.
Reference: Healthy mature businesses convert 8–15% of revenue into FCF · Growth companies often negative
Full explanation → must grow at:
▾ Exactly how this 10-year figure is computed
Forecast length: 10 years, single flat growth rate (no fade)
Terminal growth after year 10: 3.0%
Discount rate: 9.5% (the rate the model used)
Price used: $17.01 — the live price shown on this page (not frozen)
Method: solve for the constant annual growth rate that makes the discounted 10-year FCF stream + terminal value equal today's price.
Market is pricing in shrinking cash flow — often a sign of undervaluation OR a dying business. Check leverage, the cash-flow trend and the measurable financial-health screens below to tell them apart.
For reference: The market is pricing in a material multi-year contraction in cash flow (≈16.8%/yr) — a significant decline, not a flat business.
▾ How we computed this · Reality check thresholds · Assumptions
- Starting FCF/share: $4.27 (TTM)
- Discount RateDiscount Rate — The annual return you demand for taking single-stock risk instead of buying a safe Treasury or index fund.
Why it matters: Higher discount rate = stricter valuation (a stock has to produce more cash to be worth holding). Lower = more generous.
Reference: 8–12% is standard · 9–10% matches S&P 500 historical return · Below 7% is illogical for single-stock risk
Full explanation →: 9.5% — standard 8-12%; 9-10% matches S&P 500 historical return - Terminal Growth RateTerminal Growth Rate — The growth rate we assume the company holds forever, after the explicit 10-year forecast period ends.
Why it matters: It anchors the long-tail value. Cannot mathematically exceed long-term GDP growth or the company eventually becomes larger than the global economy.
Reference: 2–3% (matches long-term US GDP growth) · Above 4% is mathematically problematic
Full explanation →: 3.0% — matches long-term GDP growth - Forecast horizon: 10 years explicit + terminal perpetuity
| ≤ 0% | Priced for decline — likely undervalued OR dying business |
| 5-12% | Reasonable; sustainable for quality businesses |
| 12-18% | Demanding — strong execution required |
| 18-25% | Exceptional — few companies sustain for a decade |
| 25-35% | Heroic — historically very rare |
| 35%+ | Borderline impossible at scale |
Sustaining 30%+ cash-flow growth for a full decade at scale is exceedingly rare — the bar is brutally high.
Use the interactive calculator below to change the discount rate, growth and terminal-growth assumptions and watch the value move.
Football field: where does the price sit?
Different valuation methods produce different fair-value ranges depending on assumptions. Plotting them together lets you see at a glance whether the current price is reasonable across approaches, or only one specific lens.
Industry multiples sourced from: industry: Pharmaceuticals. See the Peer Basket section below for the peer comparison and its limited-comparables caveat.
How does TBPH stack up against its closest peers?
We take the 8 same-industry companies most similar to TBPH (similar size) and check what investors are paying for each dollar of their revenue (or profits). If TBPH is much more expensive on the same yardstick, that's a red flag — unless you have a specific reason it deserves a premium. For a leveraged business, EV/EBIT and FCF yield (both in the table) are usually more reliable than EV/Sales, because revenue multiples ignore differences in margins and debt.
▾ What's "EV / Sales" in plain English?
EV (Enterprise Value) = market cap + total debt − cash. It's "what you'd pay to buy the entire company outright" — you pay the market cap to shareholders and take over their debt, but you keep their cash. EV is fairer than market cap alone because it includes the debt the new owner inherits.
EV / Sales = EV ÷ annual revenue. So "2.5×" means investors pay $2.50 of enterprise value per $1 of yearly sales. Higher = market is paying more per dollar of sales (usually because they expect future growth or fat margins).
p25 / median / p75 are the 25th, 50th (middle), and 75th percentile of the peers' multiples. Half the peers fall between p25 and p75. The median (p50) is the typical peer — that's the benchmark we compare to.
| EV / SalesEV / Sales — For every $1 of yearly revenue, this is how many dollars investors pay to own the whole business (including debt). Why it matters: Works for pre-profit growth companies where P/E and FCF don't apply. The most apples-to-apples cross-company multiple because it ignores accounting choices. Reference: 1–3x for mature companies · 4–10x for software/SaaS · 10–20x for hypergrowth · >20x is rare and demanding Full explanation → |
2.1x / 5.6x / 7.4x |
| EV / Gross ProfitEV / Gross Profit — Enterprise value divided by gross profit — the multiple paid for what each dollar of sales contributes after direct costs. Why it matters: More refined than EV/Sales for high-margin businesses (software, marketplaces) where gross margin is the real economic engine. Reference: 8–15x for SaaS · 15–25x for hypergrowth software · >30x demanding Full explanation → |
2.4x / 2.7x / 6.4x |
Bold middle number = median peer. Half the peers trade above it, half below. Computed over 8 same-industry peers; implausible multiples excluded.
⚠️ Important caveat: peer multiples only work if the peers are genuinely comparable. Always check the peer list below — if the auto-picker grabbed micro-caps or unrelated businesses, the comparison is noise. A medical-device giant priced against tiny biotech startups won't produce a useful signal.
▾ View peer list (8)
| Ticker | Company | Industry | Mcap | EV/Sales | EV/GP | EV/EBIT | FCF Yield |
|---|---|---|---|---|---|---|---|
| XNCR | Xencor Inc | Pharmaceuticals | $881M | 7.4x | — | — | 0.4% |
| SPRY | ARS Pharmaceuticals, Inc. | Pharmaceuticals | $901M | 11.8x | — | — | 4.1% |
| PHAR | Pharming Group N.V. | Pharmaceuticals | $787M | 2.1x | 2.4x | 30.4x | 4.8% |
| PHAT | Phathom Pharmaceuticals, Inc. | Pharmaceuticals | $765M | 5.6x | 6.4x | — | 2.4% |
| XERS | Xeris Biopharma Holdings, Inc. | Pharmaceuticals | $1.1B | 4.4x | — | 51.6x | 28.6% |
| ZVRA | ZEVRA THERAPEUTICS, INC. | Pharmaceuticals | $685M | 7.0x | — | — | 11.1% |
| TLRY | Tilray Brands, Inc. | Pharmaceuticals | $642M | 0.8x | 2.7x | — | 1.2% |
| WVE | Wave Life Sciences Ltd. | Pharmaceuticals | $1.3B | 29.6x | — | — | 0.0% |
Quality & solvency checks
Cheap stocks can be cheap for a reason. These screens warn when a low valuation comes paired with structural fragility.
Why it matters: Cheap-looking stocks (low P/E or P/B) often have low Z-scores because the market knows the company is dying. Z-score warns you before you fall into a value trap.
Reference: > 3.0 = safe zone · 1.81–3.0 = grey zone · < 1.81 = distress zone
Full explanation →
The Z-score needs working capital, retained earnings, EBIT, sales and total assets from the latest balance sheet, and at least one of those isn't reported in machine-readable form here — common for foreign private issuers. We leave it blank rather than compute a distress verdict from an estimated input. It doesn't affect the reported figures in the financial tables below.
▾ The checks — what passed, what didn't (and what we couldn't measure)
-
✓ Positive net incomeNet income $105.9M in FY2025.
-
✓ Positive operating cash flowOperating cash flow $238.5M (was -$11.5M the prior year).
-
✓ Cash flow backs up reported profitOperating cash flow $238.5M vs net income $105.9M.
-
✓ Return on assets improvingReturn on assets 21.8% vs -15.9% a year ago.
-
✓ Debt load (vs assets)The filing reports no interest-bearing debt in either year (total assets $485.6M).
-
✓ Short-term liquidity (current ratio)Current ratio 10.93x vs 5.02x a year ago.
-
✗ Share count (dilution)Share count rose 5.4% (48.8M → 51.5M year-over-year).Why this matters: Issuing lots of new shares splits the pie into more pieces, shrinking your slice. Stable or falling share count protects existing owners.
-
· Pricing power (gross margin) (n/a — data not reported; not scored)
-
✓ Sales per asset (asset turnover)Asset turnover 0.22x vs 0.18x a year ago.
Missing data is never counted as a pass or a fail — it's shown as n/a and excluded from the denominator. Each check compares the company against its own prior year.
What if you assume different inputs?
Here's where we land — and what happens if you change the assumptions. Drag the sliders to set your own Discount RateDiscount Rate — The annual return you demand for taking single-stock risk instead of buying a safe Treasury or index fund.
Why it matters: Higher discount rate = stricter valuation (a stock has to produce more cash to be worth holding). Lower = more generous.
Reference: 8–12% is standard · 9–10% matches S&P 500 historical return · Below 7% is illogical for single-stock risk
Full explanation → (the annual return you demand for single-stock risk) and terminal growth; the value updates live so you can see whether the stock looks cheaper or richer. The discount rate starts at 9.5%, the figure our model used for TBPH. Open Advanced to also change beta, growth and the rate path.
Note: the calculator opens at our published value of $154.19 — it is initialised to the same scenario-weighted result, so the two match exactly on load. The moment you move a slider, the value below becomes a single-path what-if at your assumptions (not the three-scenario weighting), which is why it can differ from the headline once you've touched it.
9.5% — beta-based (CAPM), from this stock's BetaBeta — How much the stock moves when the overall market moves. 1.0 = moves with the market; 1.5 = moves 50% more than the market.
Why it matters: Higher beta = more volatile = should demand higher discount rate. Low beta stocks (utilities, consumer staples) move less.
Reference: Most stocks 0.5–1.5 · Defensives ~0.3 · High-vol tech ~1.5–2.0
Full explanation → of 0.91. The safe Treasury rate plus a premium scaled by how much more (or less) volatile the stock is than the market.
10.5% — sector/quality tier. A simpler hurdle set by industry and business durability: lower for stable, wide-moat companies; higher for speculative or micro-caps.
The headline value and this calculator start at 9.5% — the beta-based rate. Drag the slider to the other rate to see the full range.
-89.0%
At the default assumptions the flat path lands near our published value of $154.19. Move any slider to recompute it with your own.
Move any slider above to recompute this against your own assumptions.
⚙ Advanced — tinker with every input (beta, growth, rate path, margin → full intrinsic value)
TBPH is deeply undervalued by the model, trading at a significant 89.0% discount to its intrinsic valueIntrinsic Value — Our DCF model's estimate of what each share is mathematically worth based on projected cash flows.
Why it matters: Compare to current price. Below IV = potentially undervalued. Above IV = priced for growth that must actually happen.
Reference: Model-derived; quality depends on data and assumptions.
Full explanation → of $154.194. Despite positive revenue growth and a strong current ratio, the market likely discounts the stock due to its historical unprofitability (profitable only 2/5 years) and inconsistent operating cash flow (positive only 1/5 years). The primary quantifiable risk is the market's implied decline rate of 20.0%, significantly diverging from the model's 19.6% per year.
As of 3 months ago
Anatomy of a share
What you're buying per share. Bars are at the same scale so you can see the relative size of revenue, costs, cash flow, and debt — not just read them in a table.
What's free cash flow / what do these mean?
Revenue per share — how much the business earns from customers, divided by the number of shares outstanding. Top of the income statement.
Earnings per share — profit left after operating costs, interest, and taxes, per share. Two versions appear on this page and are not interchangeable: GAAP diluted EPS uses the company's weighted-average diluted share count during the reporting period (this is the "earnings" in "price-to-earnings"); net income per current share divides annual net income by today's share count. They differ whenever the share count has changed.
Owner-earnings free cash flow per share — the cash the business produces for shareholders. Savng's owner-earnings FCF subtracts capital expenditures and stock-based compensation from operating cash flow (SBC is a real dilution cost even though it's non-cash). This is deliberately more conservative than "standard" FCF, which subtracts only capital expenditures — so our figure is lower than the headline FCF you'll see elsewhere. FCF funds dividends, buybacks, debt repayment, and acquisitions; a company can report positive earnings yet negative FCF.
Debt per share — total interest-bearing borrowings divided by shares. High debt-per-share next to thin FCF-per-share is a fragility signal.
What you actually need to decide
Every stock price is a disagreement. Here's the single thing that must go right for the bulls, the single thing that breaks the thesis, and the concrete signposts to watch so you can update your view as real results arrive.
Why it matters: Compare to current price. Below IV = potentially undervalued. Above IV = priced for growth that must actually happen.
Reference: Model-derived; quality depends on data and assumptions.
Full explanation → and reduce the market's implied 20.0% decline rate.
- Next quarter's operating cash flow trend
- Net income profitability in upcoming reports
- Updates on pipeline progress and regulatory milestones
The trend, in plain numbers (FY2024 → FY2025, latest reported)
Straight from the financial statements — no model, no opinion. For a small or unprofitable company, the direction of these numbers usually tells you more than any single valuation.
- Revenue grew +67% to $107.5M.
- Free cash flow turned positive at $220.0M.
- Swung to a profit of $105.9M (from a loss the prior year).
Nothing was clearly worsening year-over-year.
Management & Leadership
Theravance Biopharma, Inc. is led by Rick E. Winningham, who has served as Chief Executive Officer since 2014. He also serves as Chairman of the Board. The company focuses on the discovery, development, and commercialization of new medicines.
What They Make
Theravance Biopharma develops and commercializes medicines for respiratory diseases and other conditions. Their products are primarily sold to healthcare providers and patients through pharmaceutical distribution channels.
End Markets
Revenue Drivers
Why Is It Priced Like This?
Why Customers Pay
The market prices TBPH at a deep 89.6% discount, likely reflecting concerns over its inconsistent profitability, having been profitable only 2 out of the last 5 years, and its operating cash flow being positive in only 1 of the last 5 years. While revenue is growing at 18.1% per year, the market's implied decline rate of 20.0% suggests skepticism about the sustainability of this growth and future cash generation.
Three Scenarios, Weighted
| Scenario | IV | Upside from today's price | Weight |
|---|---|---|---|
| Conservative | $114.30 | 571.9% | 40% |
| Base | $157.04 | 823.2% | 35% |
| Optimistic | $214.05 | 1,158.4% | 25% |
| Weighted | $154.19 | 806.5% | 100% |
Reading the last column: it is the move from today's price to each value (IV ÷ price − 1). The headline "premium/discount to model IV" measures the same gap from the value's side (price ÷ IV − 1), so the two percentages differ in size and sign by construction — e.g. a price 8% above value is a value 7.4% below price.
Business Model & Valuation
How They Make Money
The company is retiring 4% of its shares per year, boosting per-share growth, and funds its operations through a combination of existing cash and potential future equity raises or partnerships.
Free Cash Flow DCF Medium
Standard FCF DCF: positive free cash flow in a sector suited for cash-flow-based valuation. FCF negative in 4/5 years.
Show advanced inputs
| Revenue Growth | 18.1% |
| Sector Default | 10.0% |
| Best Estimate | 15.6% |
| Method | blend(70% revenue_cagr, 30% sector)+buyback(4%) |
| Growth Basis | total |
What this model does NOT do: this is a consolidated owner-earnings FCF model. Standalone segment assumptions: none. It does not project its revenue segments independently; their combined effect is embedded in the historical revenue and cash-flow trend the model extrapolates. The calculator above can only approximate a segment's impact through the single consolidated growth rate — it cannot model any one line separately. For a true segment-level view, build a separate model from the company's segment disclosures.
Maturity & Competitive Position
Moat Signals
Revenue has been growing at 18.1% per year over the last four years, from $55M to $107M.
Geography & Markets
Theravance Biopharma, Inc. is headquartered in the US and operates globally, focusing on markets where its pharmaceutical products can gain regulatory approval and commercial traction. Specific geographic revenue mix is not available from current data sources.
Geographic Risks
Market Signals
These are timing signals, not value signals — they describe the stock's recent price behavior, not what the business is worth. Use them for the "the thesis looks good, but is now the moment?" question. Each tile below explains what it's saying.
Why it matters: Short-term contrarian indicator. Extreme readings often precede mean reversion, though not always.
Reference: 30–70 normal · >70 overbought · <30 oversold
Full explanation → (14)40.9NeutralMomentum is balanced — neither overbought nor oversold.
Why it matters: When the fast line crosses above the slow line, short-term momentum is turning up; below, turning down. A timing cue, not a value signal.
Reference: Line above signal = bullish momentum · below = bearish
Full explanation →BearishLine below signalThe fast trend is below the slow trend — short-term momentum is currently downward.
Technicals describe price, not the business. A great company can have a "bearish" tape (a buying chance) and a weak one a "bullish" tape (a trap). Pair these with the valuation and health sections above.
QUALITY
Data Quality & Risk Flags (2 notes — click to expand/collapse)
Guardrail Notes (2)
- Per-share growth boosted by buybacks: the company is retiring 4% of its shares per year, which adds directly to per-share growth on top of business growth. Final per-share growth used by the model: 19.6%/yr.
- Illiquidity discount 7% applied (small/micro-cap — harder to exit, demand a margin).
FINANCIALS
Financial Statements (5-year tables — click to expand)
From Theravance Biopharma, Inc.'s SEC filings (EDGAR).
Income (5yr)
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | 107.5M | 105.9M | $2.06 |
| 2024 | 64.4M | -56.4M | $-1.15 |
| 2023 | 57.4M | -55.2M | $-1.00 |
| 2022 | 51.3M | 872.1M | $11.85 |
| 2021 | 55.3M | -199.4M | $-2.87 |
Cash Flow (5yr)
| Year | Operating CF | CapEx | − SBC & adj. | Free Cash Flow |
|---|---|---|---|---|
| 2025 | 238.5M | 42,000 | 18.5M | 220.0M |
| 2024 | -11.5M | 332,000 | 21.4M | -33.3M |
| 2023 | -27.0M | 2.5M | 25.4M | -54.9M |
| 2022 | -187.0M | 572,000 | 39.7M | -227.3M |
| 2021 | -207.9M | 3.4M | 62.1M | -273.3M |
How we define FCF: operating cash flow − capital expenditure − stock-based compensation (owner-earnings basis — SBC is a real cost to shareholders even though it's non-cash). Latest year: 238.5M − 42,000 − 18.5M (SBC & adj.) = 220.0M. This is the same owner-earnings FCF definition the valuation model uses.
Balance Sheet
| Total Assets | 485.6M |
| Total Liabilities | 188.8M (derived) |
| Equity | 296.7M |
Similar companies worth a look
Same sector and industry, similar fundamentals shape. Verify everything yourself — this list is computed mechanically and does not reflect our judgment about whether any of these are a good investment.